Ruti Aga's Six-Year Arithmetic: Two Years for the Substance, Four for the Paperwork

Ruti Aga won a half marathon in China in March. I learned this from a Thursday statement by the Athletics Integrity Unit, not from the result sheet of the race itself. That gap is the first thing worth reporting: the race has a distance, a country and a victory, and no time. Any performance judgment built on it would be invention.

On my desk there is an old habit. When a sanction lands, I write the arithmetic first and the story second. In the margin of the register last night I wrote: 2 + 4 = 6. Two years for the presence of a prohibited substance, four years for tampering with the evidence chain, six years in total, running from 10 September. Above it, circled in red pen from the wire copy: "prohibited steroid."

That phrase is wrong. The Seiko never lied to me, so I have tried never to lie to it, and I will not call a glucocorticoid an anabolic steroid just because the sentence reads better that way.

Aga is 32, Ethiopian. My register first carries her name on the 2026 Berlin page, second place, 2:18:34 in my notebook pending official confirmation; then Tokyo 2026, first place, 2:20:40. Three second-place finishes at World Marathon Majors. That classification matters, because in Ethiopian women's marathon a 2:18–2:20 athlete is respected and not top tier — the sub-2:14 range exists above her, and the world record above that. A 2:18 marathoner is not automatically selectable in her own country. Hold that fact; it decides the question of what happens after the ban.

The body that ruled is the AIU, created in 2026 as an independent unit inside World Athletics, and since then the enforcement load on road running has sat with it. It applies the WADA Code 2026 and the WADA Prohibited List. The Code's structure is plain: a substance in the sample is a presence violation, misleading an investigation is a tampering violation, and the two carry separate penalties. In this case both landed.

Then the Chinese half marathon. March, unnamed, a Label-tier road race. I know how that tier works. For East African marathoners it is the most attractive income band between Majors — appearance fee fixed and paid, field shallow, weather negotiable. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races, and the first name attached to that collision is Ruti Aga.

Here is the technical correction that the entire case hinges on. Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, class S9 on the WADA list, and it is prohibited in-competition only — by injection, oral or rectal route. Anabolic steroids sit in class S1 and are banned at all times. The distinction is large. A therapeutic knee injection is entirely legal out of competition and becomes a violation only if residues are present in competition. A road race's testing window opens at 23:59 the day before the race, so an injection given days earlier can be caught. That is what happened.

The consequence is that a legitimate defence existed. Route, timing, medical necessity — all three were arguable. A Therapeutic Use Exemption was available, or compliance with WADA's route-specific washout guidance. None of it appears to have happened. The story is therefore not about the drug. It is about the paper.

Look at the document chain in three places, because in all three the verification failed. The clinic named on the prescription did not exist. The person who issued it was a family member with no medical registration. That person claimed to have used an old prescription pad from a former workplace, and the clinic disowned the claim outright. Three independent checks, three failures. That is not an administrative slip; it is the signature of a system.

The four-year tampering sanction did not come from a document alone. It came from an interview — from statements made under questioning. That detail matters, because language and translation in AIU interviews with Ethiopian athletes have been a recurring point of contention. I am not alleging a translation failure here. I am saying that when four of six years rest on what an athlete said in a room, the conditions of that room deserve the same scrutiny as the laboratory report.

Now the part nobody is writing: the medical-governance vacuum. Chronic knee pathology is not an exception for a high-volume marathoner; it is the cost of the profession. Corticosteroid injection for synovitis is standard sports-medicine practice. The danger sits not in the drug but in the arrangement around it. A credentialed team physician would have produced records. Records would have produced a TUE conversation. A TUE conversation would have produced no article at all.

Read the 2 + 4 arithmetic carefully. A two-year base for presence is what the Code produces when the substance is Specified and intent is not established. Four years is the standard tampering sanction. The sum is six, which tells us the panel rejected the no-significant-fault mitigation that could have reduced the presence period. Backdating the ban to 10 September is procedural, not a discount — provisional suspension time counts against the sanction, and the athlete gains nothing in real terms.

What survives is the 2026 Tokyo title. The violation is anchored to the March race, and absent a finding of earlier use, results before that date are not automatically annulled. The March result and its prize money are almost certainly void, since AIU practice is to disqualify the competition where the sample was collected. The statement does not set out the disqualification scope, and that omission is the document's largest hole.

The age line is straightforward. Six years from 32 means a return at 38. Ethiopian women's marathon depth is such that a 38-year-old with a doping record is not in the selection conversation. The ban is six years on paper and a career end in effect. The drug did not end it. The decision to paper over the drug did.

Appeal remains open and I will not call it closed. The CAS window typically runs about 21 days from the reasoned decision. But what was established here is document-based — no clinic, no registration, a pad claim rejected by the clinic itself — and document-based findings are hard to overturn. Not impossible. Low value.

Here I have to argue with my own copy. One column for what happened; one for what we wished had. The second column writes itself: a federation's silence, the absence of medical support, the name of the adviser who suggested or accepted that document and who appears nowhere in the statement. Read the first column first. It contains a 32-year-old who won a Major in 2026, finished second at three more, and had a legitimate route through a sore knee. She did not take it.

I found the discrepancy on page forty-one, not as a figure of speech. In 2026, when six Indian women athletes took CAS-confirmed bans, I drafted a one-page supplement-declaration protocol and mailed it to fourteen state units. The response was close to nil. That was the day I understood that protocol is what we agreed to while we were still calm — not something negotiated inside a crisis. Aga's case had no calm moment. The knee hurt, the race was close, and somebody forged a page.

Keep a third column too, unpublished but checked: what improved, by how much, on what date. Credit here goes to the AIU for verifying that the clinic existed, that the prescriber was registered, and that the pad claim collapsed against the clinic's own account. Ten years ago that verification would not have happened. Document verification has become the real enforcement frontier, and it does not discriminate by passport — it only looks that way because wealthy federations have lawyers who make their cases quieter.

The six-year ban was not imposed for a substance with any proven endurance benefit. A glucocorticoid reduces pain and swelling; it does not lower a marathon time. What ended the career was the method of concealing the treatment. That separates this case entirely from anabolic-steroid prosecutions, and it is precisely the distinction the wire copy's single word erased. That word turned a timing-and-route case into a morality tale.

Assume for a moment that Aga had produced genuine records. The presence charge might still have been brought, but it would have sat at the no-significant-fault end — a reprimand or a substantially reduced period — and the tampering charge would not have existed. In the best case, a TUE-consistent treatment plan with correct washout timing produces no case at all. Three possible worlds: no sanction, two years, six years. The drug did not choose between them.

Those who call this disproportionate enforcement against African road runners have an argument — six years is a long time. Those who call it rigour have one too — forging a document is a denial of the investigation itself, and denying an investigation must cost more than the investigation would have, or everyone forges. Both are right and both are incomplete, because neither asks the question that matters: why did an athlete at this level not have access to real medical records? The answer is money and proximity, and no panel's decision records it.

There is a further thread. Document forgery is a criminal offence in many jurisdictions, and the AIU's jurisdiction stops short of it; referral to national authorities is possible. The statement does not say whether one occurred. That silence belongs in the record too.

The Ethiopian federation has said nothing. That absence is not accidental. When your women's marathon depth is such that one 2:18 athlete leaving does not move the selection arithmetic, institutional silence is cheap. The competitive landscape did not change with this ruling; the governance landscape did.

One more discomfort, and it is professional. Across the East African road-running cases of recent years a pattern shows: the first violation concerns a substance, the second concerns the explanation of it. If that pattern holds, there are more in the pipeline, because the same informal medical networks serve many athletes inside the same training clusters. I am not forecasting the next name. I am noting that the structure which delivered Aga here is still standing.

Count the attempts before you count the medals — a discipline I took from Anju Bobby George's attempt sheet, which I requested from the IAAF media desk in Paris in 2026. Five legal marks inside a 22-centimetre band, a bronze won on consistency rather than one jump. Apply the method here. There is no medal, only attempts: one sample, one prescription, one phone call, one interview. Add them and what emerges is not a drug story. It is the story of a system in which a relative sat where the physician should have been.

Finally a question I ask myself, because the fourth-place audit I inherited from Milkha in Rome 2026 and Los Angeles 2026, and from P.T. Usha's one-hundredth of a second, spares nobody. That generation learned to convert near-misses into mourning. Tokyo 2026 broke the spell. Will we turn this into mourning too — the poor woman caught up in her own treatment — or report it as what it is? An athlete took a prohibited substance, was caught, and then had produced a document that belonged to no clinic at all. Ask what the result was before asking what it felt like.

The question that survives belongs to next March. China's Label circuit is now a high-scrutiny zone: large appearance fees, dense East African elite fields and AIU testing inside the same race. The manager who tells an athlete to take the knee injection because nothing will be tested will be citing a case that cost six years. Whether he remembers is not the question. Whether she has a real doctor's number this time is.